Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Selecting Treatment for CLL and Managing BTK Inhibitor-Associated Toxicities

February 18th 2022

Two experts discuss their approach to selecting therapy for patients with CLL and provide insight on managing adverse events when using BTK inhibitors.

Chronic Lymphocytic Leukemia and BTK Inhibitors

February 18th 2022

Amy Goodrich, RN, MSN, CRNP, and Kirollos S. Hanna, PharmD, BCPS, BCOP, provide an overview of chronic lymphocytic leukemia (CLL) and the role BTK inhibitors play in treatment.

Clinical Implications Continued

February 18th 2022

Dr Lamanna expands on BTK clinical implications within CLL therapy.

Dr. Burger on the Changing Treatment Landscape of CLL

February 17th 2022

Jan A. Burger, MD, PhD, discusses the changing treatment landscape of chronic lymphocytic leukemia.

Dr. Choi on the Addition of Ublituximab to Ibrutinib in R/R CLL

February 16th 2022

Michael Choi, MD, discusses the results of the phase 3 GENUINE trial examining ublituximab in combination with ibrutinib vs ibrutinib alone in patients with relapsed/refractory chronic lymphocytic leukemia.

Fixed-Duration Therapy in Relapsed/Refractory CLL: Ibrutinib Plus Venetoclax

February 14th 2022

Considerations for treating patients with relapsed/refractory chronic lymphocytic leukemia with the combination of ibrutinib and venetoclax.

Fixed-Duration Therapy in Frontline CLL: Venetoclax Plus Obinutuzumab

February 14th 2022

The rationale for investigating the fixed-duration, all-oral combination regimen of venetoclax with obinutuzumab as treatment for chronic lymphocytic leukemia.

Clinical Implications of BTK Inhibitors in CLL

February 11th 2022

Dr Shah explains the clinical implications of using BTK inhibitors for CLL treatment.

Non-Covalent BTK Inhibitors

February 11th 2022

Dr Shah introduces non-covalent BTK inhibitors and clinical findings from their use in the CLL landscape.

Dr. Hill on the Potential Utility of Next-Generation PI3K Inhibitors in CLL

February 9th 2022

Brian T. Hill, MD, PhD, discusses the potential utility of next-generation PI3K inhibitors in chronic lymphocytic leukemia.

Challenges Continued

February 4th 2022

Nicole Lamanna, MD, continues her discussion on BTK inhibitor challenges.

FDA Investigates Potential Increased Risk of Death With Umbralisib in Select Lymphomas

February 4th 2022

The FDA has announced that they are investigating umbralisib (Ukoniq), an oral inhibitor of PI3K-delta and CK1-epsilon that is approved to treat patients with marginal zone lymphoma and follicular lymphoma, after initial data from the phase 3 UNITY-CLL trial revealed a potential increased risk of death in those who received the agent.

Challenges With BTK Inhibitors

February 4th 2022

Dr Lamanna explains the challenges associated with BTK inhibitors.

Acalabrutinib Shows Better Safety, Tolerability Than Ibrutinib in Relapsed/Refractory CLL

February 4th 2022

John Seymour, MD, discusses the safety of acalabrutinib vs ibrutinib in patients with chronic lymphocytic leukemia, and what findings from post-hoc analyses of the ELEVATE-RR trial mean for clinical practice.

Dr. Melenhorst on the Persistence of CD4+ CAR T-Cells in Inducing Remissions in CLL

February 2nd 2022

Jan Joseph Melenhorst, BSc, MS, PhD, discusses the persistence of CD4+ CAR T-cells in inducing remissions in patients with chronic lymphocytic leukemia.

Zanubrutinib sNDA for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Accepted in China

February 1st 2022

The China National Medical Products Administration has accepted a supplemental new drug application for zanubrutinib as a treatment option for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Chronic Lymphocytic Leukemia Treatment Landscape

January 28th 2022

Nicole Lamanna, MD, and Nirav N. Shah, MD, discuss the chronic lymphocytic leukemia treatment (CLL) landscape, including risk factors and treatment options.

Dr. Choi on Future Research Directions in CLL

January 17th 2022

Michael Choi, MD, discusses future research directions in chronic lymphocytic leukemia.

Research Reflections: Coombs Provides Insight Into Key ASH Abstracts in CLL

January 17th 2022

Dr Coombs discusses research that was presented at the 2021 ASH Annual Meeting and Exposition in chronic lymphocytic leukemia, including that with covalent and noncovalent BTK inhibitors, COVID-19 vaccinations, and time-limited combinations.

Subcutaneous Epcoritamab Demonstrates Early Activity, Favorable Tolerability in CLL

January 16th 2022

Subcutaneous epcoritamab demonstrated early activity and favorable tolerability in patients with relapsed/refractory chronic lymphocytic leukemia and high-risk features.